Miguel Bronchud: PSA Decline Below 0.2 ng/mL Signals Better Outcomes

Miguel Bronchud, Co-Founder at Regenerative Medication Options, shared on LinkedIn:

”What (if any) is the Optimum PSA to Decide Prostate Most cancers Therapy Efficacy ?

The mathematical modeling of Prostate-Particular Antigen (PSA) decline following surgical or medical castration (Androgen Deprivation Remedy, or ADT) depends on unusual differential equations (ODEs).

These fashions mix mobile kinetics (the shrinking inhabitants of most cancers cells) with intracellular manufacturing dynamics (how tightly androgen ranges management the expression of the PSA protein).

In medical apply, the instant response of whole serum PSA following the initiation of castration is mathematically noticed as a biphasic exponential decline.

First Part : A speedy, steep drop occurring throughout the first few weeks. This represents the instant clearance of circulating PSA from the blood alongside the large shut-down of androgen-regulated PSA transcription.
Second Part: A slower, extended decline lasting months. This represents the true clearance of androgen-dependent tumor cells through apoptosis (programmed cell dying).
PSA nadir : The bottom secure PSA degree achieved earlier than potential recurrence.
A number of part III medical trials have proven {that a} prostate-specific antigen (PSA) degree beneath 0.2 ng/mL is one of the best cut-off for figuring out a affected person’s prognosis.

Actual-world knowledge are missing, nonetheless, and physicians typically use different metrics—equivalent to proportion of PSA decline – to evaluate therapy response.

After therapy for metastatic prostate most cancers, a decline in prostate-specific antigen (PSA) ranges is an indicator that the therapy is efficient.

Findings from a latest real-world research revealed by Freedland et al (2026) within the journal Most cancers point out that reaching a PSA degree beneath 0.2 ng/mL is an indicator of improved affected person survival.

See: How low do it’s worthwhile to go? Affiliation between numerous prostate-specific antigen response measures and medical outcomes in metastatic castration-sensitive prostate most cancers.

To find out whether or not there’s a PSA response goal related to a positive final result, investigators analyzed Veterans Well being Administration knowledge on 4,890 sufferers with metastatic hormone-sensitive prostate most cancers who acquired testosterone deprivation remedy with or with out different remedies throughout 2018 to 2023.

Over a median follow-up of roughly 2 years, 896 sufferers died. Sufferers whose PSA ranges dropped beneath 0.2 ng/mL inside 9 months of beginning therapy had been 54% much less more likely to die than sufferers whose ranges didn’t decline this low.

No enchancment was famous in sufferers who had no less than a 90% PSA decline however didn’t obtain a PSA of lower than 0.2 ng/mL.

The findings recommend that sufferers who don’t expertise a PSA drop beneath 0.2 ng/mL could possibly be candidates for extra aggressive remedies.

Additionally, sufferers who acquired testosterone deprivation remedy plus one other drug to additional block testosterone had been extra more likely to obtain a PSA beneath 0.2 ng/mL.”